{
    "info": {
        "nct_id": "NCT06267001",
        "official_title": "A Phase III, Randomized, Double-blind Study of Tiragolumab Plus Atezolizumab Compared With Placebo Plus Atezolizumab in Participants With Completely Resected Stage IIB, IIIA, or Select IIIB, PD-L1 Positive, Non-small Cell Lung Cancer Who Have Received Adjuvant Platinum-based Chemotherapy",
        "inclusion_criteria": "* Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1\n* Histological or cytological diagnosis of Stage IIB, IIIA, and select IIIB NSCLC of either non-squamous or squamous histology\n* Participants must have had complete resection of NSCLC\n* Participants must have received between one to four cycles of adjuvant histology-based platinum doublet chemotherapy\n* Participants must have recovered adequately from surgery and from adjuvant chemotherapy\n* Tumor cell PD-L1 expression at >/= 1%\n* Adequate hematologic and end-organ function.\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
        "exclusion_criteria": "* Any history of prior NSCLC within the last 5 years\n* Any evidence of residual disease or disease recurrence following surgical resection of NSCLC, or during or following adjuvant chemotherapy\n* NSCLC known to have mutation in the epidermal growth factor receptor (EGFR) gene or an anaplastic lymphoma kinase (ALK) fusion oncogene",
        "miscellaneous_criteria": ""
    },
    "inclusion_lines": [
        {
            "line": "* Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1",
            "criterions": [
                {
                    "exact_snippets": "Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1",
                    "criterion": "ECOG performance status",
                    "requirements": [
                        {
                            "requirement_type": "value",
                            "expected_value": [
                                "0",
                                "1"
                            ]
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Histological or cytological diagnosis of Stage IIB, IIIA, and select IIIB NSCLC of either non-squamous or squamous histology",
            "criterions": [
                {
                    "exact_snippets": "Histological or cytological diagnosis",
                    "criterion": "diagnosis method",
                    "requirements": [
                        {
                            "requirement_type": "method",
                            "expected_value": [
                                "histological",
                                "cytological"
                            ]
                        }
                    ]
                },
                {
                    "exact_snippets": "Stage IIB, IIIA, and select IIIB NSCLC",
                    "criterion": "NSCLC stage",
                    "requirements": [
                        {
                            "requirement_type": "stage",
                            "expected_value": [
                                "IIB",
                                "IIIA",
                                "select IIIB"
                            ]
                        }
                    ]
                },
                {
                    "exact_snippets": "non-squamous or squamous histology",
                    "criterion": "NSCLC histology",
                    "requirements": [
                        {
                            "requirement_type": "type",
                            "expected_value": [
                                "non-squamous",
                                "squamous"
                            ]
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Participants must have had complete resection of NSCLC",
            "criterions": [
                {
                    "exact_snippets": "complete resection of NSCLC",
                    "criterion": "NSCLC resection",
                    "requirements": [
                        {
                            "requirement_type": "completeness",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Participants must have received between one to four cycles of adjuvant histology-based platinum doublet chemotherapy",
            "criterions": [
                {
                    "exact_snippets": "Participants must have received between one to four cycles of adjuvant histology-based platinum doublet chemotherapy",
                    "criterion": "adjuvant histology-based platinum doublet chemotherapy",
                    "requirements": [
                        {
                            "requirement_type": "cycles received",
                            "expected_value": {
                                "comparisons": [
                                    {
                                        "operator": ">=",
                                        "value": 1,
                                        "unit": "cycles"
                                    },
                                    {
                                        "operator": "<=",
                                        "value": 4,
                                        "unit": "cycles"
                                    }
                                ]
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Participants must have recovered adequately from surgery and from adjuvant chemotherapy",
            "criterions": [
                {
                    "exact_snippets": "Participants must have recovered adequately from surgery",
                    "criterion": "recovery from surgery",
                    "requirements": [
                        {
                            "requirement_type": "recovery",
                            "expected_value": "adequate"
                        }
                    ]
                },
                {
                    "exact_snippets": "Participants must have recovered adequately ... from adjuvant chemotherapy",
                    "criterion": "recovery from adjuvant chemotherapy",
                    "requirements": [
                        {
                            "requirement_type": "recovery",
                            "expected_value": "adequate"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Tumor cell PD-L1 expression at >/= 1%",
            "criterions": [
                {
                    "exact_snippets": "Tumor cell PD-L1 expression at >/= 1%",
                    "criterion": "tumor cell PD-L1 expression",
                    "requirements": [
                        {
                            "requirement_type": "expression level",
                            "expected_value": {
                                "operator": ">=",
                                "value": 1,
                                "unit": "%"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Adequate hematologic and end-organ function.",
            "criterions": [
                {
                    "exact_snippets": "Adequate hematologic ... function.",
                    "criterion": "hematologic function",
                    "requirements": [
                        {
                            "requirement_type": "adequacy",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "Adequate ... end-organ function.",
                    "criterion": "end-organ function",
                    "requirements": [
                        {
                            "requirement_type": "adequacy",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "Healthy volunteers allowed",
            "criterions": [
                {
                    "exact_snippets": "Healthy volunteers allowed",
                    "criterion": "volunteer health status",
                    "requirements": [
                        {
                            "requirement_type": "status",
                            "expected_value": "healthy"
                        }
                    ]
                }
            ]
        },
        {
            "line": "Must have minimum age of 18 Years",
            "criterions": [
                {
                    "exact_snippets": "minimum age of 18 Years",
                    "criterion": "age",
                    "requirements": [
                        {
                            "requirement_type": "minimum",
                            "expected_value": {
                                "operator": ">=",
                                "value": 18,
                                "unit": "Years"
                            }
                        }
                    ]
                }
            ]
        }
    ],
    "exclusion_lines": [
        {
            "line": "* Any history of prior NSCLC within the last 5 years",
            "criterions": [
                {
                    "exact_snippets": "Any history of prior NSCLC within the last 5 years",
                    "criterion": "history of prior NSCLC",
                    "requirements": [
                        {
                            "requirement_type": "time frame",
                            "expected_value": {
                                "comparisons": [
                                    {
                                        "operator": "<=",
                                        "value": 5,
                                        "unit": "years"
                                    }
                                ]
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Any evidence of residual disease or disease recurrence following surgical resection of NSCLC, or during or following adjuvant chemotherapy",
            "criterions": [
                {
                    "exact_snippets": "evidence of residual disease",
                    "criterion": "residual disease",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "disease recurrence",
                    "criterion": "disease recurrence",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "surgical resection of NSCLC",
                    "criterion": "surgical resection of NSCLC",
                    "requirements": [
                        {
                            "requirement_type": "completion",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "adjuvant chemotherapy",
                    "criterion": "adjuvant chemotherapy",
                    "requirements": [
                        {
                            "requirement_type": "completion",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* NSCLC known to have mutation in the epidermal growth factor receptor (EGFR) gene or an anaplastic lymphoma kinase (ALK) fusion oncogene",
            "criterions": [
                {
                    "exact_snippets": "NSCLC known to have mutation in the epidermal growth factor receptor (EGFR) gene",
                    "criterion": "EGFR gene mutation",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "NSCLC known to have ... an anaplastic lymphoma kinase (ALK) fusion oncogene",
                    "criterion": "ALK fusion oncogene",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                }
            ]
        }
    ],
    "miscellaneous_lines": [],
    "failed_inclusion": [],
    "failed_exclusion": [],
    "failed_miscellaneous": []
}